<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36995436</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Long COVID in autoimmune rheumatic diseases.</ArticleTitle><Pagination><StartPage>1197</StartPage><EndPage>1207</EndPage><MedlinePgn>1197-1207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-023-05319-0</ELocationID><Abstract><AbstractText>Consequences of Corona Virus Disease-19 (COVID-19) in patients with rheumatic diseases (RDs) are clinically diverse. SARS-CoV-2 infection has been associated with various autoimmune and rheumatic manifestations over the past three years. Emerging evidence points to the possibility of Long COVID predisposition in rheumatic patients due to the changes in immune regulatory response. The aim of this article was to overview data on the pathobiology of Long COVID in patients with RDs. Related risk factors, clinical characteristics, and prognosis of Long COVID in RDs were analyzed. Relevant articles were retrieved from Medline/PubMed, Scopus, and Directory of Open Access Journals (DOAJ). Diverse mechanisms of viral persistence, chronic low-grade inflammation, lasting production of autoantibodies, endotheliopathy, vascular complications, and permanent tissue damage have been described in association with Long COVID. Patients with RDs who survive COVID-19 often experience severe complications due to the immune disbalance resulting in multiple organ damage. Regular monitoring and treatment are warranted in view of the accumulating evidence.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Fedorchenko</LastName><ForeName>Yuliya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5042-1191</Identifier><AffiliationInfo><Affiliation>Department of Pathophysiology, Ivano-Frankivsk National Medical University, Halytska Str. 2, Ivano-Frankivsk, 76018, Ukraine. yufedorchenko@ifnmu.edu.ua.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zimba</LastName><ForeName>Olena</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Rheumatology and Immunology, University Hospital in Krakow, Krakow, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine N2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID-19</Keyword><Keyword MajorTopicYN="N">Rheumatic diseases</Keyword></KeywordList><CoiStatement>Both authors have no potential conflicts of interest to disclose. &#x201c;All of the byline authors meet the ICMJE criteria for authorship. We well understand privilege and responsibility of the authorship of the scientific publications. We declare that we are keeping global and/or local guidelines of research and publication ethics strictly including authorship.&#x201d;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36995436</ArticleId><ArticleId IdType="pmc">PMC10061411</ArticleId><ArticleId IdType="doi">10.1007/s00296-023-05319-0</ArticleId><ArticleId IdType="pii">10.1007/s00296-023-05319-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID Live&#x2014;coronavirus statistics&#x2014;Worldometer. https://www.worldometers.info/coronavirus/#countries. Accessed 1st February 2023</Citation></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Thronicke A, Hinse M, Weinert S, Jakubowski A, Grieb G, Matthes H. Factors associated with self-reported post/Long-COVID-a real-world data study. Int J Environ Res Public Health. 2022;19(23):16124. doi: 10.3390/ijerph192316124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph192316124</ArticleId><ArticleId IdType="pmc">PMC9738553</ArticleId><ArticleId IdType="pubmed">36498197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. How common is Long COVID? Why studies give different answers. Nature. 2022;606(7916):852e3. doi: 10.1038/d41586-022-01702-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-01702-2</ArticleId><ArticleId IdType="pubmed">35725828</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859&#x2013;866. doi: 10.1136/annrheumdis-2020-217871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792. doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011;31:1409. doi: 10.1007/s00296-011-1999-324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-011-1999-324</ArticleId><ArticleId IdType="pubmed">21800117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507&#x2013;513. doi: 10.1016/s0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318:H1084&#x2013;H1090. doi: 10.1152/ajpheart.00217.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00217.2020</ArticleId><ArticleId IdType="pmc">PMC7191628</ArticleId><ArticleId IdType="pubmed">32228252</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3&#x2013;20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17(1):46&#x2013;64. doi: 10.1038/s41581-020-00357-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-020-00357-4</ArticleId><ArticleId IdType="pmc">PMC7570423</ArticleId><ArticleId IdType="pubmed">33077917</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center For Disease Control And Prevention. JAMA. 2020;323(13):1239&#x2013;1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil A, Chanakya K, Shenoy P, Chandrashekara S, Haridas V, Kumar S, et al. A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases. BMC Rheumatol. 2022;6(1):32. doi: 10.1186/s41927-022-00264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-022-00264-0</ArticleId><ArticleId IdType="pmc">PMC9192133</ArticleId><ArticleId IdType="pubmed">35698182</ArticleId></ArticleIdList></Reference><Reference><Citation>Fike A, Hartman J, Redmond C, Williams SG, Ruiz-Perdomo Y, Chu J, et al. Risk factors for COVID-19 and rheumatic disease flare in a US cohort of latino patients. Arthritis Rheumatol. 2021;73(7):1129&#x2013;1134. doi: 10.1002/art.41656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41656</ArticleId><ArticleId IdType="pmc">PMC8014137</ArticleId><ArticleId IdType="pubmed">33455077</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattui SE, Conway R, Putman MS, Seet AM, Gianfrancesco MA, Beins K, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global rheumatology alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021;3(12):e855&#x2013;e864. doi: 10.1016/S2665-9913(21)00316-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00316-7</ArticleId><ArticleId IdType="pmc">PMC8570701</ArticleId><ArticleId IdType="pubmed">34778843</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder L, Croxford R, Drucker AM, Mendel A, Kuriya B, Touma Z, et al. COVID-19 hospitalizations, intensive care unit stays, ventilation, and death among patients with immune-mediated inflammatory diseases compared to controls. J Rheumatol. 2022;49(5):523&#x2013;530. doi: 10.3899/jrheum.211012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.211012</ArticleId><ArticleId IdType="pubmed">35105713</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan. China Ann Rheum Dis. 2020;79(8):1007&#x2013;1013. doi: 10.1136/annrheumdis-2020-217627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217627</ArticleId><ArticleId IdType="pmc">PMC7295865</ArticleId><ArticleId IdType="pubmed">32444415</ArticleId></ArticleIdList></Reference><Reference><Citation>Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19&#x2014;a systematic review of the literature. J Autoimmun. 2021;117:102592. doi: 10.1016/j.jaut.2020.102592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102592</ArticleId><ArticleId IdType="pmc">PMC7833462</ArticleId><ArticleId IdType="pubmed">33401171</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T, Takaoka A. Innate immune recognition against SARS-CoV-2. Inflamm Regen. 2023;43(1):7. doi: 10.1186/s41232-023-00259-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-023-00259-5</ArticleId><ArticleId IdType="pmc">PMC9879261</ArticleId><ArticleId IdType="pubmed">36703213</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindler E, Thiel V. SARS-CoV and IFN: too little, too late. Cell Host Microbe. 2016;19:139&#x2013;141. doi: 10.1016/j.chom.2016.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.01.012</ArticleId><ArticleId IdType="pmc">PMC7104995</ArticleId><ArticleId IdType="pubmed">26867172</ArticleId></ArticleIdList></Reference><Reference><Citation>McElvaney OJ, Hobbs BD, Qiao D, McElvaney OF, Moll M, McEvoy NL, et al. A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. EBioMedicine. 2020;61:103026. doi: 10.1016/j.ebiom.2020.103026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.103026</ArticleId><ArticleId IdType="pmc">PMC7543971</ArticleId><ArticleId IdType="pubmed">33039714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17&#x2013;41. doi: 10.1002/JLB.3COVR0520-272R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3COVR0520-272R</ArticleId><ArticleId IdType="pmc">PMC7323250</ArticleId><ArticleId IdType="pubmed">32534467</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J-M, Rojas M, Salinas ML, et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20:102947. doi: 10.1016/j.autrev.2021.102947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102947</ArticleId><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Baimukhamedov C. How long is Long COVID. Int J Rheum Dis. 2022 doi: 10.1111/1756-185X.14494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14494</ArticleId><ArticleId IdType="pmc">PMC9878254</ArticleId><ArticleId IdType="pubmed">36468196</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui D, Wang Y, Huang L, Gu X, Huang Z, Mu S, et al. Rheumatic symptoms following coronavirus disease 2019 (COVID-19): a chronic post-COVID-19 condition. Open Forum Infect Dis. 2022;9(6):ofac170. doi: 10.1093/ofid/ofac170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac170</ArticleId><ArticleId IdType="pmc">PMC8992351</ArticleId><ArticleId IdType="pubmed">35611349</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodr&#xed;guez Y, Zapata E, Ram&#xed;rez-Santana C, et al. Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis. 2022;225(12):2155&#x2013;2162. doi: 10.1093/infdis/jiac017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera J, Rodr&#xed;guez T, Pallar&#xe9;s M, Castrej&#xf3;n I, Gonz&#xe1;lez T, Vallejo-Slocker L, et al. Prevalence of post-COVID-19 in patients with fibromyalgia: a comparative study with other inflammatory and autoimmune rheumatic diseases. BMC Musculoskelet Disord. 2022;23(1):471. doi: 10.1186/s12891-022-05436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-022-05436-0</ArticleId><ArticleId IdType="pmc">PMC9117853</ArticleId><ArticleId IdType="pubmed">35590317</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaruso C, Carlo Stella N, Mariani G, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095&#x2013;2097. doi: 10.1007/s10067-020-05180-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05180-7</ArticleId><ArticleId IdType="pmc">PMC7251560</ArticleId><ArticleId IdType="pubmed">32462425</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898&#x2013;907. doi: 10.1111/cts.12953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12953</ArticleId><ArticleId IdType="pmc">PMC8212749</ArticleId><ArticleId IdType="pubmed">33306235</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia-Ramos AE, Martin-Nares E, Hernandez-Molina G. New onset of autoimmune diseases following COVID-19 diagnosis. Cells. 2021;10(12):3592. doi: 10.3390/cells10123592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123592</ArticleId><ArticleId IdType="pmc">PMC8700122</ArticleId><ArticleId IdType="pubmed">34944099</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. medRxiv. 2021 doi: 10.1101/2021.01.27.21250559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.27.21250559</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Han T, Chen J, Hou C, Hua L, He S. Clinical and autoimmune characteristics of severe and clinical cases of COVID-19. Clin Transl Sci. 2020;13:1077&#x2013;1086. doi: 10.1111/cts.12805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Essien F, Chastant L, McNulty C, Hubbard M, Lynette L, Carroll M. COVID-19-induced psoriatic arthritis: a case report. Ther Adv Chronic Dis. 2022;13:20406223221099333. doi: 10.1177/20406223221099333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221099333</ArticleId><ArticleId IdType="pmc">PMC9128051</ArticleId><ArticleId IdType="pubmed">35620185</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M, Ramonell R, Nguyen D, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21:1506&#x2013;1516. doi: 10.1038/s41590-020-00814-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00814-z</ArticleId><ArticleId IdType="pmc">PMC7739702</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran L, Dontaraju VS, Troyer J, Sahota J. New onset systemic lupus erythematosus after COVID-19 infection: a case report. AME Case Rep. 2022;6:14. doi: 10.21037/acr-21-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acr-21-55</ArticleId><ArticleId IdType="pmc">PMC9010314</ArticleId><ArticleId IdType="pubmed">35475008</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6(6):CD013652. doi: 10.1002/14651858.CD013652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013652</ArticleId><ArticleId IdType="pmc">PMC7387103</ArticleId><ArticleId IdType="pubmed">32584464</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al (2021) More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021. 2021.01.27.21250617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, et al. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2022;8(2):e002587. doi: 10.1136/rmdopen-2022-002587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2022-002587</ArticleId><ArticleId IdType="pmc">PMC9475962</ArticleId><ArticleId IdType="pubmed">36104117</ArticleId></ArticleIdList></Reference><Reference><Citation>Strumiliene E, Zeleckiene I, Bliudzius R, Samuilis A, Zvirblis T, Zablockiene B, et al. Follow-up analysis of pulmonary function, exercise capacity, radiological changes, and quality of life two months after recovery from SARS-CoV-2 pneumonia. Medicina. 2021;57(6):568. doi: 10.3390/medicina57060568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57060568</ArticleId><ArticleId IdType="pmc">PMC8229364</ArticleId><ArticleId IdType="pubmed">34204878</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100463</ArticleId><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Borst B, et al. Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis. 2020;73(5):e1089&#x2013;e1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717214</ArticleId><ArticleId IdType="pubmed">33220049</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, et al. Characterizing Long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Bai W, Yue J, Qin L, Zhang C, Xu S, et al. Eight months follow-up study on pulmonary function, lung radiographic, and related physiological characteristics in COVID-19 survivors. Sci Rep. 2021;11(1):13854. doi: 10.1038/s41598-021-93191-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-93191-y</ArticleId><ArticleId IdType="pmc">PMC8257634</ArticleId><ArticleId IdType="pubmed">34226597</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingery JR, Safford MM, Martin P, Lau JD, Rajan M, Wehmeyer GT, et al. Health status, persistent symptoms, and effort intolerance one year after acute COVID-19 infection. J Gen Intern Med. 2022;37(5):1218&#x2013;1225. doi: 10.1007/s11606-021-07379-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-021-07379-z</ArticleId><ArticleId IdType="pmc">PMC8786200</ArticleId><ArticleId IdType="pubmed">35075531</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Yang C, An X, Xiong Y, Shang Y, He J, et al. Follow-up study on COVID-19 survivors one year after discharge from hospital. Int J Infect Dis. 2021;112:173&#x2013;182. doi: 10.1016/j.ijid.2021.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.017</ArticleId><ArticleId IdType="pmc">PMC8434916</ArticleId><ArticleId IdType="pubmed">34520845</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway R, Nikiphorou E, Demetriou CA, Low C, Leamy K, Ryan JG, et al. Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic. Ir J Med Sci. 2023;9:1&#x2013;6. doi: 10.1007/s11845-022-03265-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-022-03265-7</ArticleId><ArticleId IdType="pmc">PMC9827440</ArticleId><ArticleId IdType="pubmed">36622628</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Rodr&#xed;guez-Jim&#xe9;nez J, Fuensalida-Novo S, Palacios-Ce&#xf1;a M, G&#xf3;mez-Mayordomo V, Florencio LL, et al. Myalgia as a symptom at hospital admission by severe acute respiratory syndrome coronavirus 2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study. Pain. 2021;162(12):2832&#x2013;2840. doi: 10.1097/j.pain.0000000000002306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000002306</ArticleId><ArticleId IdType="pubmed">33863864</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha SI, Samaan SF, Ibrahim RA, El-Sehsah EM, Youssef MK. Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity? Eur Cytokine Netw. 2021;32(4):83&#x2013;88. doi: 10.1684/ecn.2021.0471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1684/ecn.2021.0471</ArticleId><ArticleId IdType="pmc">PMC8831681</ArticleId><ArticleId IdType="pubmed">35118946</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubchenko S, Kril I, Nadizhko O, Matsyura O, Chopyak V. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol Int. 2022;42(9):1523&#x2013;1530. doi: 10.1007/s00296-022-05146-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05146-9</ArticleId><ArticleId IdType="pmc">PMC9159383</ArticleId><ArticleId IdType="pubmed">35650445</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla AK, Atal S, Banerjee A, Jhaj R, Balakrishnan S, Chugh PK, et al. An observational multi-centric COVID-19 sequelae study among health care workers. Lancet Reg Health Southeast Asia. 2023;10:100129. doi: 10.1016/j.lansea.2022.100129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2022.100129</ArticleId><ArticleId IdType="pmc">PMC9744681</ArticleId><ArticleId IdType="pubmed">36531928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper JE, Uner M, Priemer DS, Rosenberg A, Chen L. Muscle biopsy findings in a case of sars-cov-2-associated muscle injury. J Neuropathol Exp Neurol. 2021;80(4):377&#x2013;378. doi: 10.1093/jnen/nlaa155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlaa155</ArticleId><ArticleId IdType="pmc">PMC7799012</ArticleId><ArticleId IdType="pubmed">33355335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277:2251&#x2013;2261. doi: 10.1007/s00405-020-05965-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00405-020-05965-1</ArticleId><ArticleId IdType="pmc">PMC7134551</ArticleId><ArticleId IdType="pubmed">32253535</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes-Ibarra M, Oliveira CLP, Orsso CE, Landi F, Marzetti E, Prado CM. The impact of Long COVID-19 on muscle health. Clin Geriatr Med. 2022;38(3):545&#x2013;557. doi: 10.1016/j.cger.2022.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cger.2022.03.004</ArticleId><ArticleId IdType="pmc">PMC8934728</ArticleId><ArticleId IdType="pubmed">35868672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ursini F, Ciaffi J, Mancarella L, Lisi L, Brusi V, Cavallari C, et al. Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. RMD Open. 2021;7(3):e001735. doi: 10.1136/rmdopen-2021-001735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001735</ArticleId><ArticleId IdType="pmc">PMC8384499</ArticleId><ArticleId IdType="pubmed">34426540</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiantian C, Jing Z, Yiwen M, Yiming Y, Haifeng Y, Feng H, et al. COVID-19 causing death in a rheumatoid arthritis patient who retested positive for SARS-CoV-2 RNA: a case report. Int J Rheum Dis. 2023 doi: 10.1111/1756-185X.14555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14555</ArticleId><ArticleId IdType="pubmed">36599657</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinones-Moya H, Valle AO, Camargo-Coronel A, Jimenenez-Balderas FJ, Bernal-Enriquez MB, Madinabeitia-Rodr&#xed;guez P, et al. Long COVID in patients with rheumatologic disease: a single center observational study. Indian J Rheumatol. 2023 doi: 10.4103/injr.injr_118_22.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/injr.injr_118_22</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormile I, Mormile M, Rea G, Petraroli A, Barbieri V, de Paulis A, Rossi FW. Spontaneous pneumo-mediastinum in a post-COVID-19 patient with systemic sclerosis. Healthcare. 2022;10(3):529. doi: 10.3390/healthcare10030529.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10030529</ArticleId><ArticleId IdType="pmc">PMC8953142</ArticleId><ArticleId IdType="pubmed">35327007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcin Mutlu M, Taubmann J, Wacker J, Tascilar K, Fagni F, Gerner M, et al. Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis-A case report and literature review. Front Med. 2022;9:934169. doi: 10.3389/fmed.2022.934169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.934169</ArticleId><ArticleId IdType="pmc">PMC9381861</ArticleId><ArticleId IdType="pubmed">35991632</ArticleId></ArticleIdList></Reference><Reference><Citation>Fineschi S. Case report: systemic sclerosis after covid-19 infection. Front Immunol. 2021;12:686699. doi: 10.3389/fimmu.2021.686699.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686699</ArticleId><ArticleId IdType="pmc">PMC8273695</ArticleId><ArticleId IdType="pubmed">34262566</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra A, Kahaleh B. Systemic sclerosis (SSc) after COVID-19: a case report. Cureus. 2022;14(3):e23179. doi: 10.7759/cureus.23179.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.23179</ArticleId><ArticleId IdType="pmc">PMC9009972</ArticleId><ArticleId IdType="pubmed">35444873</ArticleId></ArticleIdList></Reference><Reference><Citation>Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sj&#xf6;gren&#x2019;s syndrome. Nat Rev Rheumatol. 2013;9:544&#x2013;556. doi: 10.1038/nrrheum.2013.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2013.110</ArticleId><ArticleId IdType="pubmed">23857130</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito-Zer&#xf3;n P, Acar-Denizli N, Rom&#xe3;o VC, Armagan B, Seror R, Carubbi F, et al. Post-COVID-19 syndrome in patients with primary Sj&#xf6;gren&#x2019;s syndrome after acute SARS-CoV-2 infection. Clin Exp Rheumatol. 2021;39(Suppl 133 6):57&#x2013;65. doi: 10.55563/clinexprheumatol/0anatx.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/0anatx</ArticleId><ArticleId IdType="pubmed">34874821</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Townsend L, Morrin H, Ahmad A, Comerford C, Karampini E, et al. Persistent endotheliopathy in the pathogenesis of Long COVID syndrome. J Thromb Haemost. 2021;19(10):2546&#x2013;2553. doi: 10.1111/jth.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kr&#xfc;ger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631&#x2013;637. doi: 10.1002/path.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O, Merino E, Leon-Ramirez JM, et al. Post-acute COVID-19 syndrome Incidence and risk factors: a mediterranean cohort study. J Infect. 2021;82(3):378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q, Li J, Hu X, Bai Y, Zheng Y, Gao Z. Follow-ups on persistent symptoms and pulmonary function among post-acute COVID-19 patients: a systematic review and meta-analysis. Front Med. 2021;8:702635. doi: 10.3389/fmed.2021.702635.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.702635</ArticleId><ArticleId IdType="pmc">PMC8448290</ArticleId><ArticleId IdType="pubmed">34540862</ArticleId></ArticleIdList></Reference><Reference><Citation>British Society for Immunology (2020) Long-Term Immunological Health Consequences of COVID-19. Available at https://www.immunology.org/sites/default/files/BSI_Briefing_Note_August_2020_FINAL.pdf.</Citation></Reference><Reference><Citation>Ali RMM, Ghonimy MBI. Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients. Egypt J Radiol Nucl Med. 2021;52:101. doi: 10.1186/s43055-021-00484-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43055-021-00484-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan RT, Gopalan D, Howard L, Vicente A, Park M, Manalan K, et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir Med. 2021;9:107&#x2013;116. doi: 10.1016/S2213-2600(20)30407-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30407-0</ArticleId><ArticleId IdType="pmc">PMC7833494</ArticleId><ArticleId IdType="pubmed">33217366</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G. Wilson KC (2020) COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. Lancet Respir Med. 2020;8(9):839&#x2013;842. doi: 10.1016/S2213-2600(20)30349-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30349-0</ArticleId><ArticleId IdType="pmc">PMC7398671</ArticleId><ArticleId IdType="pubmed">32758440</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis ciac. 2022 doi: 10.1093/cid/ciac722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Ruiz J, Lomel&#xed;n-Gasc&#xf3;n J, Lira-Luna J, P&#xe9;rez-Fragoso A, Tapia-Conyer R, Nu&#xf1;ez-Aguirre M, et al. FANSY POSTCOV: a composite clinical immunological predictive index for post-covid-19 syndrome unveils distinctive features in a cohort study of mild to critical patients. Clin Transl Med. 2021;11:e623. doi: 10.1002/ctm2.623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.623</ArticleId><ArticleId IdType="pmc">PMC8611773</ArticleId><ArticleId IdType="pubmed">34841707</ArticleId></ArticleIdList></Reference><Reference><Citation>Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419&#x2013;e426. doi: 10.1016/S2665-9913(21)00059-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00059-X</ArticleId><ArticleId IdType="pmc">PMC7993930</ArticleId><ArticleId IdType="pubmed">33786454</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465&#x2013;469. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. doi: 10.1136/bmj.m1849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1849</ArticleId><ArticleId IdType="pmc">PMC7221473</ArticleId><ArticleId IdType="pubmed">32409561</ArticleId></ArticleIdList></Reference><Reference><Citation>Majewski D, Majewska KA, Naskr&#x119;cka M, Grygiel-G&#xf3;rniak B. Chloroquine and hydroxychloroquine&#x2014;safety profile of potential COVID-19 drugs from the rheumatologist's perspective. Ann Agric Environ Med. 2021;28(1):122&#x2013;126. doi: 10.26444/aaem/127766.</Citation><ArticleIdList><ArticleId IdType="doi">10.26444/aaem/127766</ArticleId><ArticleId IdType="pubmed">33775077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 doi: 10.1016/j.ijantimicag.2020.105949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId><ArticleId IdType="pmc">PMC7102549</ArticleId><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fihn SD, Perencevich E, Bradley SM. Caution needed on the use of chloroquine and hydroxychloroquine for coronavirus disease 2019. JAMA Netw Open. 2020;3(4.23):e209035. doi: 10.1001/jamanetworkopen.2020.9035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.9035</ArticleId><ArticleId IdType="pubmed">32330276</ArticleId></ArticleIdList></Reference><Reference><Citation>Dos Reis Neto ET, Kakehasi AM, de Medeiros PM, Ferreira GA, Marques CDL, da Mota LMH, et al. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol. 2020;60(1):32. doi: 10.1186/s42358-020-00134-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-020-00134-8</ArticleId><ArticleId IdType="pmc">PMC7282202</ArticleId><ArticleId IdType="pubmed">32517786</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030&#x2013;2040. doi: 10.1056/NEJMoa2022926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022926</ArticleId><ArticleId IdType="pmc">PMC7556338</ArticleId><ArticleId IdType="pubmed">33031652</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SSY, Xu C. Hydroxychloroquine: is there a role in long COVID? Clin Rheumatol. 2023;25:1&#x2013;2. doi: 10.1007/s10067-023-06514-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-023-06514-x</ArticleId><ArticleId IdType="pmc">PMC9874177</ArticleId><ArticleId IdType="pubmed">36695924</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin YH, Shin JI, Moon SY, Jin HY, Kim SY, Yang JM, et al. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021;3(10):e698&#x2013;e706. doi: 10.1016/S2665-9913(21)00151-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00151-X</ArticleId><ArticleId IdType="pmc">PMC8213376</ArticleId><ArticleId IdType="pubmed">34179832</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwala SR, Vijayvargiya M, Pandey P. Avascular necrosis as a part of 'Long COVID-19'. BMJ Case Rep. 2021;14(7):e242101. doi: 10.1136/bcr-2021-242101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-242101</ArticleId><ArticleId IdType="pmc">PMC8256728</ArticleId><ArticleId IdType="pubmed">34215639</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee MD, Waddell JP, Kudo PA, Schemitsch EH, Richards RR. Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: a report of 15 cases. CMAJ. 2001;164(2):205&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC80680</ArticleId><ArticleId IdType="pubmed">11332313</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, et al. Hydroxychloroquine as prophylaxis for COVID-19: a review. Front Pharmacol. 2020;11:605185. doi: 10.3389/fphar.2020.605185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.605185</ArticleId><ArticleId IdType="pmc">PMC7744418</ArticleId><ArticleId IdType="pubmed">33343376</ArticleId></ArticleIdList></Reference><Reference><Citation>Coskun BN, Yagiz B, Pehlivan Y, Dalkilic E. Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic. Adv Rheumatol. 2021;61(1):55. doi: 10.1186/s42358-021-00211-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-021-00211-6</ArticleId><ArticleId IdType="pmc">PMC8414473</ArticleId><ArticleId IdType="pubmed">34479631</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum JT, Hamilton H, Choi D, Weisman MH, Reveille JD, Winthrop KL. Biologics spondylitis and COVID-19. Ann Rheum Dis. 2020;79(12):1663&#x2013;1665. doi: 10.1136/annrheumdis-2020-217941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217941</ArticleId><ArticleId IdType="pubmed">32522741</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L, Orban ZS, Koralnik IJ. Case report: treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence. Front Med. 2022;9:1003103. doi: 10.3389/fmed.2022.1003103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1003103</ArticleId><ArticleId IdType="pmc">PMC9537824</ArticleId><ArticleId IdType="pubmed">36213654</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, et al. (2022) Association between BNT162b2 vaccination and Long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328(7):676&#x2013;678. doi: 10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Felten R, Dubois M, Ugarte-Gil MF, Chaudier A, Kawka L, Bergier H, et al. Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatol. 2021;3(4):e243&#x2013;e245. doi: 10.1016/S2665-9913(21)00039-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00039-4</ArticleId><ArticleId IdType="pmc">PMC7906671</ArticleId><ArticleId IdType="pubmed">33655219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022;377:e069676. doi: 10.1136/bmj-2021-069676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci. 2021;428:117607. doi: 10.1016/j.jns.2021.117607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117607</ArticleId><ArticleId IdType="pmc">PMC8330139</ArticleId><ArticleId IdType="pubmed">34365148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, He Y, Terkeltaub R, Sun M, Ran Z, Xu X, et al. Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination. Ann Rheum Dis. 2022;81(8):1189&#x2013;1193. doi: 10.1136/annrheumdis-2022-222199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222199</ArticleId><ArticleId IdType="pmc">PMC9279754</ArticleId><ArticleId IdType="pubmed">35277390</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ahmad M, Al Rasheed M, Altourah L, Rodriguez-Bouza T, Shalaby N. Lupus anticoagulant activity and thrombosis post COVID-19 vaccination. Blood Coagul Fibrinolysis. 2023;34(1):75&#x2013;78. doi: 10.1097/MBC.0000000000001161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBC.0000000000001161</ArticleId><ArticleId IdType="pubmed">35946452</ArticleId></ArticleIdList></Reference><Reference><Citation>VanDerVeer SJ, Maier KD, Hill EM. Rheum-CoV-2 vaccination case series. J Clin Rheumatol. 2022 doi: 10.1097/RHU.0000000000001906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001906</ArticleId><ArticleId IdType="pmc">PMC9940785</ArticleId><ArticleId IdType="pubmed">36219608</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>